Revisiting the Immune Frontier in Soft Tissue Sarcomas

Area of Science:

• Oncology
• Immunotherapy
• Soft Tissue Sarcomas

Background:

• Soft tissue sarcomas (STS) are a diverse group of cancers with limited advanced treatment options.
• Immune checkpoint inhibitors (ICIs) have shown modest, histology-dependent efficacy in STS.
• This review synthesizes recent immuno-oncology advances in STS.

Purpose of the Study:

• To review current immuno-oncology strategies for soft tissue sarcomas.
• To highlight emerging approaches for overcoming resistance to immunotherapy in STS.
• To discuss potential improvements in patient outcomes.

Main Methods:

• Literature review of recent advances in immuno-oncology for STS.
• Analysis of clinical trial data for combination therapies and cellular therapies.
• Examination of tumor microenvironment factors influencing immunotherapy response.

Main Results:

• Clinically significant activity of ICIs observed in specific STS subtypes (e.g., undifferentiated pleomorphic sarcoma, angiosarcoma).
• Combination therapies (ICI + chemo/radiation/TKIs/immune modulators) demonstrate enhanced antitumor activity.
• Engineered T-cell therapies are a standard for synovial sarcoma and expanding to other histologies.
• Tumor microenvironment characterization aids patient selection and trial design.

Conclusions:

• Immunotherapy is transforming STS treatment, but ICI monotherapy benefits a subset.
• Rational combination strategies and cellular therapies offer broader efficacy.
• Biomarker-driven, histology-specific trials are crucial for realizing immunotherapy's full potential in STS.